by mpzzqmvj | Jun 21, 2022 | Press Releases
Presentation by Professor Caroline Hastings, MD, Chair of the Phase 3 Trappsol® Cyclo™ Program Steering Committee and the Global Principal Investigator for the Company’s ongoing TransportNPC™ study evaluating Trappsol® Cyclo™ for the...
by mpzzqmvj | May 18, 2022 | Press Releases
GAINESVILLE, Fla. – Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a late clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients...
by mpzzqmvj | May 12, 2022 | Press Releases
– Continued advancement of lead development program evaluating Trappsol® Cyclo™ for Niemann-Pick Disease Type C1 (NPC1) in ongoing global pivotal study (TransportNPC™) – Phase 2 study of Trappsol® Cyclo™ for the treatment of...
by mpzzqmvj | May 9, 2022 | Press Releases
– Live video webcast with moderated fireside chat with members of the Cyclo Therapeutics leadership team and Global Principal Investigator for the Phase 3 study, Professor Caroline Hastings, MD, on Monday, May 16th at 2:00 PM ET GAINESVILLE, Fla. – Cyclo...
by mpzzqmvj | Mar 29, 2022 | Press Releases
– Live video webcast with moderated fireside chat with members from the Cyclo Therapeutics management team and featuring Key Opinion Leader, Cynthia A. Lemere, PhD on Tuesday, April 5th at 1:00 PM ET GAINESVILLE, Fla. – Cyclo Therapeutics, Inc. (Nasdaq:...
